Track topics on Twitter Track topics that are important to you
A multicentric study will evaluate whether peri-procedural tight glycemic control during angioplasty revascularization for acute coronary syndrome (ACS) reduces circulating inflammatory cytokines and thrombus formation in hyperglycaemic patients. Moreover, the investigators will assess whether the tight glycemic control during the first month from coronary event reduces the incidence of coronary stent restenosis at 6-months from PCI.
The study design will be structured on the basis of protocol Yale. Upon emergency wards admission, all patients will be assigned to undergo prompt coronary revascularization. After PCI procedures, hyperglycemic patients will be randomly assigned to intensive glucose control (IGC group) and those treated with conventional glucose control (CGC group). In the patients with In the CGC group, continuous insulin infusion of 50 IU Actrapid HM (Novo Nordisk) in 50 ml NaCl (0.9% using a Perfusor-FM pump) will be started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell <180 mg/dl, insulin infusion will be tapered and eventually stopped. In the IGC group, insulin infusion will be started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. During insulin infusion, oral feeding will be stopped and parenteral nutrition (13±5 Kcal/kg-1/day-1) will be started. After the start of insulin infusion protocol a glycemic control will be provided every hour in order to obtain three consecutive values that were within the goal range. The infusion will be lasted until stable glycemic goal (ICG group: 80-140 mg/dl; CGC group: 180-200 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI in both group. In IGC group, the treatment goal will be a fasting blood glucose level of 90-140 mg/dl and a non-fasting level of <180 mg/dl. In CGC group, the treatment goal will be fasting blood glucose and postprandial levels of <200 mg/dl. With regard to the full medical therapy, the protocol stated that the use of concomitant treatment should be as uniform as possible and according to evidence-based international guidelines for ACS. After 30 days from PCI, all patients with established diabetes and newly diagnosed diabetes will be managed and followed for 6 month after PCI, as outpatients, to maintain HbA1c <7% and blood glucose level of 90-140 mg/dl and a non-fasting level of <180 mg/dl.
Coronary Angiography Coronary angiograms at baseline, immediately after PCI, and at 6 months will be performed in at least 2 orthogonal views after intracoronary nitroglycerin. Minimum lumen diameter (MLD) and mean reference diameter (RD), obtained by averaging 5-mm segments proximal and distal to the target lesion location, will be used to calculate diameter stenosis as follows: (1-MLD/RD)X100. Late loss will the change in MLD from final PCI to follow-up. In-stent analysis will be confined to the stent itself, and in-segment analysis will be included the stent plus 5-mm segments proximal and distal to the stent. Binary restenosis will be defined as a <50% diameter stenosis. Qualitative analysis will be done with standard published methods.
IVUS Imaging and Analysis IVUS at baseline, immediately after PCI, and at 6 months will be performed with iLab, Galaxy, and ClearView or In Vision Gold with 20-MHz EagleEye catheters. IVUS imaging will be performed with motorized pullback at 0.5 mm/s to include the stent and >5 mm segments proximal and distal to the stent. IVUS studies will be archived onto super-VHS tape, CD-ROM, or DVD and will be sent to an independent, treatment-allocation- blinded, IVUS core laboratory for quantitative and qualitative analyses with validated planimetry software. Quantitative analysis will include measurement every 1 mm of the external elastic membrane (EEM), stent, and lumen cross-sectional areas (CSAs). Plaque plus media CSA will be calculated as EEM minus lumen. Neointimal hyperplasia (NIH) will be calculated as stent minus lumen. Once a complete set of CSA measurements will be obtained, intrastent and stent-edge volumes (EEM, plaque plus media, stent,lumen, and NIH) will be calculated with Simpson's rule and normalized for stent and reference segment length. Percent net volume obstruction will be calculated as NIH divided by stent volume.
Qualitative analysis will include stent malapposition (blood speckle behind stent struts), categorized as persistent (visible both at baseline and follow-up), resolved (visible only at baseline), and late acquired (only visible at follow-up); intrastent plaque and/or thrombus protrusion (IVUS cannot reliably differentiate between plaque and thrombus protruding through stent struts); stent fracture (absence of struts over more than one third of the stent circumference); aneurysm(lumen >50% larger than the proximal reference); and edge dissection.
Allocation: Randomized, Control: Active Control, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Dept. of Medicine, Second university of Naples
Not yet recruiting
Second University of Naples
Published on BioPortfolio: 2014-07-23T21:11:45-0400
This trial is conducted in Europe. The aim of this research is to compare the efficacy and safety of treatment with NPH insulin and insulin detemir. You will be treated with either insuli...
The purpose of this study is to determine if by using insulin analog (Glargine and lispro insulin) with an insulin pen the investigators are able to obtain a higher rate of correct timing ...
Primary objective of the study is to test whether an intensified insulin therapy incorporating the target of normal fasting glucose (
This study will help us understand the possible beneficial effects of insulin in inflammation. Inflamamtion is considered to be the cause of atherosclerosis and heart disease.
Patients with Type 2 diabetes and severe insulin resistance with very large insulin requirements who have failed all previous insulin regimens using nonconcentrated forms of insulin (U100 ...
The role of insulin-degrading enzyme (IDE), a metalloprotease with high affinity for insulin, in insulin clearance remains poorly understood.
Insulin resistance, defined as attenuated sensitivity responding to insulin, impairs insulin action. Direct causes and molecular mechanisms of insulin resistance have thus far remained elusive. Here w...
Insulin enters the brain from the blood via a saturable transport system. It is unclear how insulin is transported across the blood-brain barrier (BBB). Using two models of the signalling-related insu...
While the β-cells secrete insulin, it is the liver with its first-pass insulin extraction (FPE) that regulates the amount of insulin allowed into circulation for action on target tissues. The metabol...
Despite their obvious advantages of making insulin injections less frequent and reducing discomfort for diabetic patients, various controlled release formulations of insulin still have some problems c...
A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS.
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. It can be caused by the presence of INSULIN ANTIBODIES or the abnormalities in insulin receptors (RECEPTOR, INSULIN) on target cell surfaces. It is often associated with OBESITY; DIABETIC KETOACIDOSIS; INFECTION; and certain rare conditions. (from Stedman, 25th ed)
An insulin preparation that is designed to provide immediate and long term glycemic control in a single dosage. Biphasic insulin typically contains a mixture of REGULAR INSULIN or SHORT-ACTING INSULIN combined with a LONG-ACTING INSULIN.
Insulin formulation containing substance which delays or retards time period of the absorption of insulin.
A preparation of insulin and zinc chloride in the form of a crystalline suspension. Typically the duration of ultralente insulin activity lasts between 18-30 hours after dosage.
Cardiology is a specialty of internal medicine. Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...
Acute Coronary Syndromes ACS
Acute Coronary Syndromes (ACS) is an umbrella term for situations where the blood supplied to the heart muscle is suddenly blocked. Treatment for acute coronary syndrome includes medicines and a procedure known as angioplasty, during which doctors inflat...
A stent is a small mesh tube that's used to treat narrow or weak arteries. Arteries are blood vessels that carry blood away from your heart to other parts of your body. A stent is placed in an artery as part of a procedure called angioplasty. &...